Ionis Pharmaceuticals, Inc.

IONS

$68.94

Name : Ionis Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $10,988,432,384.00

EPSttm : -1.76

Ionis Pharmaceuticals, Inc.

$68.94

0.12%

$0.08

Float Short %

7.57

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

-1.96

EPS Last/This Y

1.12

EPS This/Next Y

0.02

Price

68.97

Target Price

72.18

Analyst Recom

1.63

Performance Q

60.96

Relative Volume

0.78

Beta

0.32

Ticker: IONS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	IONS	60.98	0.32	0.04	55587
2025-09-09	IONS	64.39	0.31	0.14	56178
2025-09-10	IONS	63.97	0.31	1.60	56567
2025-09-11	IONS	64.04	0.32	0.46	56633
2025-09-12	IONS	63.15	0.32	3.05	56706
2025-09-15	IONS	61.13	0.33	3.31	57306
2025-09-16	IONS	61.33	0.36	0.06	58593
2025-09-17	IONS	61.17	0.35709497723228	0.57294429708223	58712
2025-09-18	IONS	61.7	0.36	0.43	58747
2025-09-22	IONS	61.3	0.39	0.96	38331
2025-09-23	IONS	62.55	0.41	0.35	38581
2025-09-24	IONS	63.92	0.41	0.08	38824
2025-09-25	IONS	62.89	0.41	0.13	39098
2025-09-26	IONS	64.1	0.41	1.65	39091
2025-09-29	IONS	64.14	0.42	0.13	39503
2025-09-30	IONS	65.4	0.41	0.33	40321
2025-10-01	IONS	65.79	0.41	0.06	40926
2025-10-02	IONS	68.4	0.41	0.69	41159
2025-10-03	IONS	69.03	0.42	0.49	40950
2025-10-06	IONS	69.04	0.43	1.42	41710
2025-10-07	IONS	68.97	0.42	0.02	41662
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	IONS	61.00	-43.5	-313.0	-1.89
2025-09-09	IONS	64.38	-43.5	-345.9	-1.89
2025-09-10	IONS	63.96	-43.5	-311.3	-1.89
2025-09-11	IONS	64.04	-43.5	-315.4	-1.89
2025-09-12	IONS	63.14	-43.5	-307.3	-1.89
2025-09-15	IONS	61.10	-43.5	-296.9	-1.89
2025-09-16	IONS	61.31	-43.5	-317.0	-1.89
2025-09-17	IONS	61.14	-43.5	-313.5	-1.89
2025-09-18	IONS	61.77	-43.5	-320.5	-1.89
2025-09-19	IONS	61.02	-43.5	-308.6	-1.89
2025-09-22	IONS	61.36	-43.5	-318.3	-1.89
2025-09-23	IONS	62.55	-43.5	-325.9	-1.89
2025-09-24	IONS	63.92	-43.5	-327.1	-1.89
2025-09-25	IONS	62.97	-43.5	-306.6	-1.89
2025-09-26	IONS	64.09	-43.5	-324.9	-1.89
2025-09-29	IONS	64.17	-42.6	-315.8	-1.92
2025-09-30	IONS	65.39	-42.6	-325.7	-1.92
2025-10-01	IONS	65.80	-42.6	-318.3	-1.92
2025-10-02	IONS	68.39	-42.6	-336.8	-1.92
2025-10-03	IONS	69.18	-42.6	-321.4	-1.92
2025-10-06	IONS	69.04	-42.6	-320.2	-1.92
2025-10-07	IONS	68.97	-42.6	-314.7	-1.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	IONS	-31.09	0.43	6.82
2025-09-09	IONS	-31.09	0.43	6.82
2025-09-10	IONS	-32.40	0.43	6.82
2025-09-11	IONS	-33.59	0.43	6.64
2025-09-12	IONS	-33.59	0.43	6.64
2025-09-15	IONS	-33.59	1.07	6.64
2025-09-16	IONS	-33.94	1.07	6.64
2025-09-17	IONS	-33.94	1.07	6.64
2025-09-18	IONS	-33.94	1.07	6.64
2025-09-19	IONS	-33.94	1.07	6.64
2025-09-22	IONS	-33.94	1.08	6.64
2025-09-23	IONS	-33.94	1.08	6.64
2025-09-24	IONS	-33.94	1.08	6.64
2025-09-25	IONS	-33.94	1.08	7.57
2025-09-26	IONS	-33.94	1.08	7.57
2025-09-29	IONS	-33.94	1.09	7.57
2025-09-30	IONS	-33.94	1.09	7.57
2025-10-01	IONS	-38.35	1.09	7.57
2025-10-02	IONS	-38.35	1.09	7.57
2025-10-03	IONS	-41.95	1.09	7.57
2025-10-06	IONS	-41.95	1.09	7.57
2025-10-07	IONS	-41.95	1.09	7.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.85

Avg. EPS Est. Current Quarter

-1.03

Avg. EPS Est. Next Quarter

-1.11

Insider Transactions

-41.95

Institutional Transactions

1.09

Beta

0.32

Average Sales Estimate Current Quarter

131

Average Sales Estimate Next Quarter

145

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.7

Max Drawdown 5-Year %

-60

Target Price

72.18

P/E

Forward P/E

PEG

P/S

11.63

P/B

17.37

P/Free Cash Flow

EPS

-1.85

Average EPS Est. Cur. Y

-1.92

EPS Next Y. (Est.)

-1.89

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-28.36

Relative Volume

0.78

Return on Equity vs Sector %

-67.6

Return on Equity vs Industry %

-54

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

-314.7

Ionis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1069

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

stock quote shares IONS – Ionis Pharmaceuticals, Inc. Stock Price stock today

news today IONS – Ionis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IONS – Ionis Pharmaceuticals, Inc. yahoo finance google finance

stock history IONS – Ionis Pharmaceuticals, Inc. invest stock market

stock prices IONS premarket after hours

ticker IONS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IONS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y